NCT06758557 - A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | Biotech Hunter

Enrollment

282

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions

Advanced NSCLCAdvanced Endometrial Cancer

Interventions

DRUG

HB0025

HB0025 IV every 3 weeks (q3w)

DRUG

Pemetrexed

500 mg/m² iv d1

DRUG

Paclitaxel

175 mg/m² iv d1

DRUG

Carboplatin

AUC 5 iv d1

Trial Locations (14)

0312

RECRUITING

Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding

0451

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

0379

RECRUITING

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang

0371

RECRUITING

Henan Cancer Hospital, Zhengzhou

0518

RECRUITING

The First People'S Hospital of Lianyungãng, Lianyungang

024

RECRUITING

Liaoning Cancer Hospital＆Institute, Shenyang

0531

RECRUITING

Central Hospital Affiliated to Shandong First Medical University, Jinan

0539

RECRUITING

Linyi Cancer Hospital, Linyi

0536

RECRUITING

Weifang People'S Hospital, Weifang

021

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

0351

RECRUITING

Shanxi Cancer hospital, Taiyuan

029

RECRUITING

The First Affiliated Hospitalof Xi'an Jiaotong University, Xi’an

0871

RECRUITING

The First Affiliated Hospital of Kunming Medical University, Kunming

0571

RECRUITING

The First Affiliated Hospitalzhejiang University School of Medicine, Hangzhou